Für die üblichen Verdächtigen.
https://pubmed.ncbi.nlm.nih.gov/33010094/[*quote*]
Public health information (CDC) Research information (NIH) SARS-CoV-2 data (NCBI) Prevention and treatment information (HHS)
Oncologist
. 2020 Dec;25(12):e1930-e1955. doi: 10.1002/onco.13548. Epub 2020 Nov 7.
Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study
Michael Frass 1 2, Peter Lechleitner 3, Christa Gründling 4, Claudia Pirker 5, Erwin Grasmuk-Siegl 5, Julian Domayer 5, Maximilian Hochmair 5, Katharina Gaertner 6, Cornelia Duscheck 7, Ilse Muchitsch 8, Christine Marosi 7, Michael Schumacher 9, Sabine Zöchbauer-Müller 7, Raj K Manchanda 10, Andrea Schrott 11, Otto Burghuber 12
Affiliations collapse
Affiliations
1Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology and Institute for Homeopathic Research, Vienna, Austria.
2Scientific Society for Homeopathy (WissHom), Koethen, Germany.
3Hospital of Lienz, Department of Medicine, Lienz, Austria.
4General Practitioner, Enns, Austria.
5Department of Respiratory and Critical Care Medicine, Respiratory Oncology Unit, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
6Institute of Complementary Medicine, University of Bern, Inselspital, Bern, Switzerland.
7Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology, Vienna, Austria.
8Austrian Chamber of Pharmacists, Department Vienna, HomResearch, Interdisciplinary Homeopathic Research Group, Vienna, Austria.
9Elisabethinenspital, Department of Medicine, Linz, Austria.
10Central Council for Research in Homeopathy, Ministry of AYUSH, Government of India and LMHI, West Delhi, Delhi, India.
11StatistikAmbulanz, Consulting Company, Leobendorf, Austria.
12Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for Lung Health, Otto Wagner Hospital and Sigmund Freud University, Medical School, Vienna, Austria.
PMID: 33010094 PMCID: PMC8108047 DOI: 10.1002/onco.13548
Free PMC article
Erratum in
Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
Frass M, Lechleitner P, Gründling C, Pirker C, Grasmuk-Siegl E, Domayer J, Hochmair M, Gaertner K, Duscheck C, Muchitsch I, Marosi C, Schumacher M, Zöchbauer-Müller S, Manchanda RK, Schrott A, Burghuber O.
Oncologist. 2021 Mar;26(3):e523. doi: 10.1002/onco.13693.
PMID: 33660386 Free PMC article. No abstract available.
Abstract
Lessons learned: Conventional medicine and homeopathy work well together. Quality of life improves with additive homeopathy in patients with non-small cell lung cancer (NSCLC). Survival improves with additive homeopathy in patients with NSCLC.
Background: Patients with advanced non-small cell lung cancer (NSCLC) have limited treatment options. Alongside conventional anticancer treatment, additive homeopathy might help to alleviate side effects of conventional therapy. The aim of the present study was to investigate whether additive homeopathy might influence quality of life (QoL) and survival in patients with NSCLC.
Methods: In this prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter, phase III study, we evaluated the possible effects of additive homeopathic treatment compared with placebo in patients with stage IV NSCLC, with respect to QoL in the two randomized groups and survival time in all three groups. Treated patients visited the outpatients' centers every 9 weeks: 150 patients with stage IV NSCLC were included in the study; 98 received either individualized homeopathic remedies (n = 51) or placebo (n = 47) in a double-blinded fashion; and 52 control patients without any homeopathic treatment were observed for survival only. The constituents of the different homeopathic remedies were mainly of plant, mineral, or animal origin. The remedies were manufactured by stepwise dilution and succussion, thereby preparing stable Good Manufacturing Practice grade formulations.
Results: QoL as well as functional and symptom scales showed significant improvement in the homeopathy group when compared with placebo after 9 and 18 weeks of homeopathic treatment (p < .001). Median survival time was significantly longer in the homeopathy group (435 days) versus placebo (257 days; p = .010) as well as versus control (228 days; p < .001). Survival rate in the homeopathy group differed significantly from placebo (p = .020) and from control (p < .001).
Conclusion: QoL improved significantly in the homeopathy group compared with placebo. In addition, survival was significantly longer in the homeopathy group versus placebo and control. A higher QoL might have contributed to the prolonged survival. The study suggests that homeopathy positively influences not only QoL but also survival. Further studies including other tumor entities are warranted.
Trial registration: ClinicalTrials.gov NCT01509612.
Keywords: Additive homeopathy; Adult oncology; Complementary and alternative medicine; Global health status; Lung cancer; Survival.
© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Figures
Figure 1
Figure 1 Kaplan‐Meier estimates of overall survival…
Figure 2
Figure 2 Study protocol.Abbreviations: BL, baseline; verum,…
Figure 3
Figure 3 CONSORT diagram.
Cited by 1 article
Attention Dysregulation in Breast Cancer Patients Following a Complementary Alternative Treatment Routine: A Double-Blind Randomized Trial.
Dolev T, Ben-David M, Shahadi I, Freed Y, Zubedat S, Aga-Mizrachi S, Brand Z, Galper S, Jacobson G, Avital A.
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211019470. doi: 10.1177/15347354211019470.
PMID: 34027702 Free PMC article.
References
Cancer facts and statistics. American Cancer Society Web site. 2016.
http://www.cancer.org/research/cancerfactsstatistics/index. Accessed February 22, 2017.
Jemal A, Siegel R, Xu J et al. Cancer statistics. CA Cancer J Clin 2010;60:277–300. - PubMed
Molina JR, Yang P, Cassivi SD et al. Non‐small cell lung cancer: Epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584–594. - PMC - PubMed
Hirsch FR, Scagliotti GV, Mulshine JL et al. Lung cancer: Current therapies and new targeted treatments. Lancet 2017;389:299–311. - PubMed
Ettinger DS, Wood DE, Aisner DL et al. Non‐small cell lung cancer, version 2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2017;15:504–535. - PubMed
Show all 33 references
Publication types
Research Support, Non-U.S. Gov't
Associated data
ClinicalTrials.gov/NCT01509612
Related information
MedGen
LinkOut - more resources
Full Text Sources
Europe PubMed Central
PubMed Central
Wiley
Medical
ClinicalTrials.gov
NCBI Literature Resources MeSH PMC BookShelf
FOLLOW NCBI
Follow NLM
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
NLM
NIH
HHS
USA.gov
[*/quote*]
